TSHA

Taysha Gene Therapies, Inc.

• PUBT·3d ago

  Taysha Gene Therapies posts corporate deck highlighting TSHA-102 gene therapy program for Rett syndrome

• Dow Jones·6d ago

  Taysha Gene Therapies Is Maintained at Buy by Goldman Sachs

• Benzinga·6d ago

  Goldman Sachs Maintains Buy on Taysha Gene Therapies, Raises Price Target to $13

• Simply Wall St·07/16 12:31

  Does Rett Trial Data and Share Offering Reshape the Bull Case for Taysha Gene Therapies (TSHA)?

• TipRanks·07/13 16:05

  Taysha Gene Therapies falls -11.0%

• PUBT·07/10 22:55

  Taysha Gene Therapies President, Head of R&D Sukumar Nagendran disposes of 200,000 common shares for $1.25 million

• Simply Wall St·07/10 12:31

  Taysha Gene Therapies (TSHA) Could Be 49% Below Fair Value After Russell Index Drop

• Simply Wall St·07/08 07:34

  Will Russell Index Removals and New Rett Data Change Taysha Gene Therapies' (TSHA) Narrative?

• Seeking Alpha·07/02 18:33

  Neurogene: 'Hold' EMBOLDEN Study Underway And 2nd Half 2027 Topline Data

• Dow Jones·07/02 13:06

  Taysha Gene Therapies Price Target Maintained With a $11.00/Share by Citizens

• Benzinga·07/02 12:56

  Citizens Reiterates Market Outperform on Taysha Gene Therapies, Maintains $11 Price Target

• TipRanks·07/01 11:50

  Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX), Taysha Gene Therapies (TSHA) and Zymeworks (ZYME)

• Dow Jones·06/30 20:02

  Taysha Gene Therapies Price Target Maintained With a $12.00/Share by Needham

• Dow Jones·06/30 20:02

  Taysha Gene Therapies Is Maintained at Buy by Needham

• TipRanks·06/30 18:35

  Buy Rating Reaffirmed on Taysha’s Superior Trial Rigor and Safety Profile; $12 Price Target Maintained